Optibrium

#Biomedical research #Drug discovery #European Union #Funding #Optibrium #Sustainability

EU-Funded PhD programme to advance sustainable drug discovery

Optibrium has partnered with Tallinn University of Technology (TalTech) to co-supervise an EU-funded PhD position as part of the INNOCHEMBIO programme1. This research project will focus on developing more accurate metabolism models that will reduce the reliance on costly laboratory experiments while improving speed, efficiency and sustainability in drug discovery. Read More

#News

#3D modelling #Artificial intelligence (AI) #BioPharmics #Computational chemistry #Mergers and acquisitions #Molecular Biology #Optibrium

Optibrium acquires BioPharmics

AI drug discovery company Optibrium has acquired 3D drug design specialist BioPharmics. BioPharmics’ CEO, Dr Ajay Jain, and Director of Applied Science, Dr Ann Cleves, will join the Optibrium team, respectively focusing on R&D and Application Science in the newly-created BioPharmics Division. BioPharmics has… Read More

#Business & Investment #News